2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
06/14/2018OpGen Modifies Terms of Debt with Merck Global Health Innovation Fund
GAITHERSBERG, Md., June 14, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior Secured Promissory Note (the “Note”), dated June 28, 2017, to extend the maturity of the note and to pay accrued interest through the issuance of shares of common stock. The Note is issued to Merck Global Health Innovation Fund, LLC (Merck GHI). The modifications provide that (1) accrued and unpaid in... 
 Printer Friendly Version
06/12/2018OpGen Presents Data at ASM Microbe 2018 Demonstrating High Accuracy of Acuitas® for Predicting Antibiotic Resistance in Urine Specimens
90% accuracy data presented for rapid antibiotic resistance prediction using Acuitas AMR Gene Panel and Acuitas Lighthouse on urine clinical specimens Prospective clinical trial in Colombia demonstrates 57% improvement in survival and reductions in antibiotic usage when OpGen rapid diagnostic test used GAITHERSBERG, Md., June 12, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the presentation of data from the first phase of its Acuitas® urine clinical verification study d... 
 Printer Friendly Version
06/05/2018OpGen’s Acuitas® AMR Gene Panel u5.47 Data to be Presented at ASM Microbe 2018
Company Sponsors Symposium on Rapid Pathogen Detection and Prediction of Antimicrobial Resistance in Urinary Tract Infections GAITHERSBURG, Md., June 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® AMR Gene Panel u5.47 (RUO) and Acuitas Lighthouse® Knowledgebase will be presented at ASM Microbe 2018 being held June 7-11, 2018 in Atlanta. OpGen’s Senior Vice President of Research and Development, Terry Walker, Ph.D., will present the following: ... 
 Printer Friendly Version
05/08/2018OpGen Reports First Quarter 2018 Financial Results and Provides a Business Update
Revenue increases 10% to $0.8 million, net loss decreases 39% to $3.0 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three months ended March 31, 2018, and provided a summary of recent business highlights. Total revenue for the first quarter of 2018 was $0.85 million, up 10% from the $0.77 million reported in the first quarter of 2017. The net l... 
 Printer Friendly Version
05/01/2018OpGen Announces Date of First Quarter 2018 Financial Results Conference Call
GAITHERSBURG, Md., May 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, May 8, 2018. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern time to discuss the Company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: (888) 883-4599 International Dial-In Numb... 
 Printer Friendly Version
04/24/2018OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug Resistance Gene Profiles at ECCMID
DNA Sequencing prediction results and evaluation of Acuitas Resistome Test for infection control presented GAITHERSBURG, Md., April 24, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented analytical validation results for the Acuitas® AMR Gene Panel u5.47 (RUO) for detection of multi-drug resistant pathogens and antibiotic resistance genes and the use of test results to predict antibiotic resistance using the bioinformatics capabilities of the Acuitas Ligh... 
 Printer Friendly Version
04/19/2018OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital intensive care units in Colombia. The study showed significant improvement in survival and reductions in antibiotic usage for patients receiving the OpGen rapid diagnostic test.  Results will be presented at ... 
 Printer Friendly Version
03/15/2018OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., March 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three and 12 months ended December 31, 2017, and provided a summary of recent business highlights. Total revenue for the fourth quarter of 2017 was... 
 Printer Friendly Version
03/13/2018OpGen Announces Collaborator in Verification Study for Acuitas® Test
Study to evaluate potential utility in management of complicated urinary tract infections GAITHERSBURG, Md., March 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it is collaborating with Beth Israel Deaconess Medical Center (BIDMC) in Boston on a verification study for OpGen’s Acuitas® AMR Gene Panel u5.47 Assay and Acuitas Lighthouse® Knowledgebase.  The principal investigator at BIDMC is Stefan Riedel, M.D., Ph.D., D(ABMM), FCAP, Associate Medical Director of th... 
 Printer Friendly Version
03/05/2018OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
GAITHERSBURG, Md., March 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report its fourth quarter and fiscal year 2017 financial results after close of market on Thursday, March 15, 2018. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern time to discuss the Company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: (888) 883-4599 International Dial-In Number: (484) 653-68... 
 Printer Friendly Version
03/01/2018OpGen to Present at the Cowen and Company 38th Annual Health Care Conference
GAITHERSBURG, Md., March 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that Evan Jones, Chairman and Chief Executive Officer of the Company, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 8:40 a.m. Eastern time. The conference will be held March 12-14, 2018 at The Boston Marriott Copley Place. To listen to the presentation live, investors may visit the investor relations section of OpGen’s ... 
 Printer Friendly Version
02/13/2018OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
Test rapidly detects 47 antimicrobial resistance markers directly from urine and bacterial isolates GAITHERSBURG, Md., Feb. 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s real-time PCR technology in the company’s Acuitas® AMR Gene Panel Tests.  The first test, the Research Use Only (RUO) AMR Gene Panel u5.47, is available for infection control purposes and pharmaceutical surveillance r... 
 Printer Friendly Version
02/07/2018OpGen Announces Closing of $12 Million Public Offering
GAITHERSBURG, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million. The Company intends to use the proceeds for research and development, including funding the continued development and manufacturing of its Acuitas® AMR Gene Panels, including its Acuitas AMR Gene Panel u5... 
 Printer Friendly Version
02/05/2018OpGen Regains Compliance With Nasdaq Listing Requirements
GAITHERSBURG, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’s stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market.  In addition, the Company has been informed that it is in compliance with all applicable listing standards of The Nasdaq Capital Market and that therefore its hearing before the Nasdaq Hearings Panel, which had be... 
 Printer Friendly Version
02/02/2018OpGen Announces Pricing of $12 Million Upsized Public Offering
GAITHERSBURG, Md., Feb. 02, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 3,692,307 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one-half of a share of common stock. The units are being offered at a public offering price of $3.25 per unit. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Each common warrant h... 
 Printer Friendly Version
02/01/2018OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
GAITHERSBURG, Md., Feb. 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has introduced a Research Use Only (RUO) Acuitas® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test was developed to detect the most common bacterial causes of cUTI directly from urine (E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, E. faecalis) and isolated colonies. Additionally, the gene panel detects 47 gene targets that convey resistance to antibi... 
 Printer Friendly Version
01/17/2018OpGen Announces Execution of Reverse Stock Split
GAITHERSBURG, Md., Jan. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it will implement a 1-for-25 reverse stock split of its common stock. The Company filed an amendment to its Certificate of Incorporation to effect the reverse stock split on January 17, 2018.  The Company expects that the Company's common stock will trade on a split-adjusted basis under the symbol “OPGN” at the beginning of trading on January 19, 2018, and the warrants to purchase common stoc... 
 Printer Friendly Version